ArticleNature communications2024
Highly multiplexed design of an allosteric transcription factor to sense new ligands.
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- A systematic transcriptomic atlas and predictive framework for metabolite-driven T cell state transitions.iScience · 2026Article
- Using enantioselective biosensors to evolve asymmetric biocatalysts.Nature chemical biology · 2026Article
- Ligify 2.0: a web server for predicted small molecule biosensors.Nucleic acids research · 2026Article
- Thermodynamic Frontiers in Hemoglobin-Inspired Polymer Science for Diagnosis and Modulation of Neurodegenerative Diseases.Cell biochemistry and function · 2026Review
- The Fragmented Nature of Biosensor Development: Challenges and Paths to Mitigation.Biosensors · 2026Review
- Engineering Biosensors to Enhance Monoterpene Indole Alkaloid Production in Yeast.bioRxiv : the preprint server for biology · 2026Article
- Analysis and engineering of quorum sensing-based communications between bacteria and fungi.mBio · 2026Review
- Design-driven optimization of low-cost reagent formulations for reproducible and high-yielding cell-free gene expression.Nature communications · 2026Article
- Programming Next-Generation Synthetic Biosensors by Genetic Circuit Design.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Scavenging for Hydroxybenzoic Acids inBiomolecules · 2026Article
- groovDB in 2026: a community-editable database of small molecule biosensors.Nucleic acids research · 2026Article
- Leveraging artificial intelligence for efficient microbial production.Bioresource technology · 2026Review
- Unusually broad-spectrum small-molecule sensing using a single protein scaffold.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Active learning-guided optimization of cell-free biosensors for lead testing in drinking water.Nature communications · 2025Article
- Directed Evolution in Escherichia coli for Novel Ligand-Binding Regulators: Evolving a Progesterone-Responsive Transcription Factor to Bind Cortisol.Current protocols · 2025Article
- Advancements and Prospects in DNA-Based Bioanalytical Technology for Environmental Toxicant Detection.JACS Au · 2025Review
- A cell-free biosensor signal amplification circuit with polymerase strand recycling.Nature chemical biology · 2025Article
Corrections and comments
- Update of
Authors and funding
13 authors.
Funding
Abstract
Allosteric transcription factors (aTF) regulate gene expression through conformational changes induced by small molecule binding. Although widely used as biosensors, aTFs have proven challenging to design for detecting new molecules because mutation of ligand-binding residues often disrupts allostery. Here, we develop Sensor-seq, a high-throughput platform to design and identify aTF biosensors that bind to non-native ligands. We screen a library of 17,737 variants of the aTF TtgR, a regulator of a multidrug exporter, against six non-native ligands of diverse chemical structures - four derivatives of the cancer therapeutic tamoxifen, the antimalarial drug quinine, and the opiate analog naltrexone - as well as two native flavonoid ligands, naringenin and phloretin. Sensor-seq identifies biosensors for each of these ligands with high dynamic range and diverse specificity profiles. The structure of a naltrexone-bound design shows shape-complementary methionine-aromatic interactions driving ligand specificity. To demonstrate practical utility, we develop cell-free detection systems for naltrexone and quinine. Sensor-seq enables rapid and scalable design of new biosensors, overcoming constraints of natural biosensors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.